AnaptysBio has been granted a patent for an IL-33-binding agent that treats autoimmune diseases. The agent comprises specific immunoglobulin heavy and light chains. This innovation offers a promising method for treating IL-33 responsive disorders in mammals. GlobalData’s report on AnaptysBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AnaptysBio, Personalized cancer vaccines was a key innovation area identified from patents. AnaptysBio's grant share as of May 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of autoimmune disease using il-33 binding protein
A recently granted patent (Publication Number: US11999783B2) discloses a method for treating autoimmune diseases using an interleukin-33 (IL-33) binding protein. The protein consists of an immunoglobulin heavy chain with specific CDR sequences and an immunoglobulin light chain with corresponding CDR sequences. The patent covers the treatment of various autoimmune diseases, including Crohn's disease, rheumatoid arthritis, psoriasis, ankylosing spondylitis, lupus erythematosus, and scleroderma, using this IL-33 binding protein.
Furthermore, the patent specifies that the IL-33 binding protein can be an antibody, an antibody conjugate, or an antigen-binding fragment thereof. It also details different forms of the binding protein, such as F(ab')2, Fab', Fab, Fv, scFv, dsFv, dAb, or a single chain binding polypeptide. The half-life of the IL-33 binding protein is crucial, falling between 30 minutes and 45 days, and it must bind to IL-33 with a KD less than or equal to 1 nanomolar. Additionally, the patent highlights that the IL-33 binding protein can be specifically an IgG1 antibody, emphasizing its potential in treating autoimmune diseases effectively.
To know more about GlobalData’s detailed insights on AnaptysBio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
